Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-05-18
2009-11-24
Bunner, Bridget E (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000, C530S324000
Reexamination Certificate
active
07622443
ABSTRACT:
The disclosure provides, among other things, novel angiogenesis-related nucleic acids, polypeptides and methods of use.
REFERENCES:
patent: 2004/0120955 (2004-06-01), Anderson et al.
patent: 0561172 (1993-09-01), None
patent: 0682113 (1995-11-01), None
patent: WO-00/55173 (2000-09-01), None
patent: WO-00/61623 (2000-10-01), None
patent: WO-01/57190 (2001-08-01), None
patent: WO-01/77289 (2001-10-01), None
patent: WO-02/079492 (2002-10-01), None
Delisser et al., “Platelet Endothelial Cell Adhesion Molecule (CD31),”Current Topics In Microbiology and Immunology184:37-45(1993).
Marra et al., Accession No. AA267694 (Mar. 21, 1997).
Osborn et al., “Direct Expression Cloning of Vascular Cell Adhesion Molecule1, A Cytokine-Induced Endothelial Protein That Binds to Lymphocytes,”Cell59:1203-1211(1989).
Genbank ref. No. XM—148854.
Genbank ref No. XP—148854.
Bork and Bairoch, 1996, Go hunting in sequence databases but watch out for the traps, Trends in Genet. 12(10):425427.
Bork, 2000, Powers and Pitfalls in Sequence Analysis: The 70% Hurdle, Genome Res. 10:398-400.
Brenner, 1999, Errors in genome annotation, Trends in Genet. 15:132-133.
Doerks, 1998, Protein annotation: detective work for function prediction, Trends in Genet. 14(6):248-250.
Ngo et al., 1995, The Protein Folding Problem and Tertiary Structure Prediction, Chapter 14: Computational Complexity Protein Structure Prediction, and the Levinthal Paradox, pp. 492-495.
Skolnick and Fetrow, 2000, From genes to protein structure and function: novel applications of computational approached in the genomic era, Trends in Genet. 18:34-39.
Smith and Zhang, 1997, The challenges of genome sequence annotation of “The devil is in the details,” Nature Biotech. 15:1222-1223.
Staton et al., 2004, Current methods for assaying angiogenesis in vitro and in vivo, Int. J. Exp. Path. 85:233-248.
Wells, 1990, Additivity of Mutational Effects in Proteins, Biochem. 29(37):8509-8517.
Antikainen et al., “Altering protein specificity: techniques and applicaitons,”Bioorganic&Medicinal Chemistry, 13:2701-2716 (2005).
Armstrong, et al., “ECSM2, An Endothelial Specific Filamin A Binding Protein That Mediates Chemotaxis,”Arterioscler Thromb Vasc Biol, 28:1-7 (2008).
Auerbach, et al. “Angiogenisis Assays: A Critical Overview,”Clinical Chemistry, 49(1):32-40 (2003).
Ferrer-Costa, et al., “Characterization of Compensated Mutations in Terms of Structural and Physico-Chemical Properties,”J. Mol. Biol., 365:249-256 (2007).
Ponce et al., “The Chick Chorioallantoic Membrane as an In Vivo Angiogenesis Model,”Current Protocols in Cell Biology, Supplement 18:19.5.1-19.5.6 (2003).
Genbank ref. No. XM—148854, Date: May 17, 2002.
Genbank ref No. XP—148854, Date: May 17, 2002.
Anderson David J.
Shin Donghun
Wang Hai U.
Bunner Bridget E
California Institute of Technology
Howard Zachary C
McCarter & English LLP
LandOfFree
Method for inhibiting pro-angiogenic activities of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for inhibiting pro-angiogenic activities of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for inhibiting pro-angiogenic activities of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4078016